Common Contracts
50 similar Employment Agreement contracts by Prime Medicine, Inc., Black Diamond Therapeutics, Inc., Centessa Pharmaceuticals PLC, others
EMPLOYMENT AGREEMENTEmployment Agreement • November 7th, 2024 • MeridianLink, Inc. • Services-prepackaged software • California
This Employment Agreement (“Agreement”) is made between MeridianLink, Inc., a Delaware corporation (including its successors and assigns, the “Company”), and Laurence E. Katz (the “Executive”) and is effective as on the first day of the Executive’s employment with the Company, which is anticipated to be April 1, 2024 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • November 5th, 2024 • Black Diamond Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made between Black Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), and Erika Jones (the “Executive”) and is effective as of May 23, 2023 (the “Effective Date”). This Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the offer letter between the Executive and the Company dated October 6, 2019 (the “Prior Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 14th, 2024 • Absci Corp • Services-commercial physical & biological research • Washington
This Employment Agreement (“Agreement”) is made between Absci Corporation, a Delaware corporation (the “Company”), and Shelby Walker (the “Executive”).
DB1/ 147697253.1 1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made by and between Centessa Pharmaceuticals LLC (the “Company”) and John Crowley, C.P.A. (the “Executive”) and is effective as of June 5, 2024 (the “Effective...Employment Agreement • August 13th, 2024 • Centessa Pharmaceuticals PLC • Pharmaceutical preparations • Massachusetts
EMPLOYMENT AGREEMENTEmployment Agreement • August 8th, 2024 • Rapport Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made between Rapport Therapeutics, Inc., a Delaware corporation (the “Company”), and Cheryl Gault (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Offer Letter between the Executive and the Company dated June 29, 2023 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • August 8th, 2024 • Rapport Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made between Rapport Therapeutics, Inc., a Delaware corporation (the “Company”), and Abraham N. Ceesay (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Offer Letter between the Executive and the Company dated December 12, 2022 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • August 8th, 2024 • MeridianLink, Inc. • Services-prepackaged software • California
This Employment Agreement (“Agreement”) is made between MeridianLink, Inc., a Delaware corporation (including its successors and assigns, the “Company”), and Elias Olmeta (the “Executive”) and is effective as on the first day of the Executive’s employment with the Company, which is anticipated to be August 26, 2024 (the “Effective Date”).
SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 8th, 2024 • Monte Rosa Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (this “Agreement”) is made between Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), and Jennifer Champoux (the “Executive”) and is effective as of May 28, 2024 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 8th, 2024 • Rapport Therapeutics, Inc. • Pharmaceutical preparations • Michigan
This Employment Agreement (“Agreement”) is made between Rapport Therapeutics, Inc., a Delaware corporation (the “Company”), and Troy Ignelzi (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Offer Letter between the Executive and the Company dated October 24, 2023 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • April 29th, 2024 • Cullinan Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made between Cullinan Therapeutics, Inc., a Delaware corporation (the “Company”), and Mary Kay Fenton (the “Executive”) and is effective as of the Executive’s first day of employment with the Company, which will be April 29, 2024 (the “Effective Date”). This Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation any term sheet.
CERTAIN CONFIDENTIAL INFORMATION MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EMPLOYMENT AGREEMENTEmployment Agreement • March 28th, 2024 • Centessa Pharmaceuticals PLC • Pharmaceutical preparations • Delaware
This Employment Agreement (this “Agreement”) is made by and between Centessa Pharmaceuticals, Inc. (the “U.S. Subsidiary”), a wholly owned subsidiary of Centessa Pharmaceuticals plc (“Parent”, with Parent, the U.S. Subsidiary and their respective subsidiaries and other affiliates referred to herein as the “Company”) and Antoine Yver (the “Executive”) and is effective as of March 30, 2022 (the “Effective Date”). This Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment offer letter between the Executive and the Company dated as of April 16, 2021 (the “Prior Agreement”) and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • March 28th, 2024 • Invivyd, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (“Agreement”) is made between Adagio Therapeutics, Inc., a Delaware corporation (the “Company”), and Peter Schmidt (the “Executive”) and is effective as of November 9, 2020 (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the offer letter between the Executive and the Company dated November 9, 2020 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • March 26th, 2024 • Allurion Technologies, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (“Agreement”) is made between Allurion Technologies, Inc., a Delaware corporation (the “Company”), and Brendan Gibbons (the “Executive”) and is made effective as of January 29, 2024 (the “Effective Date”)
EMPLOYMENT AGREEMENTEmployment Agreement • March 18th, 2024 • MeridianLink, Inc. • Services-prepackaged software • California
This Employment Agreement (“Agreement”) is made between MeridianLink, Inc., a Delaware corporation (including its successors and assigns, the “Company”), and Laurence E. Katz (the “Executive”) and is effective as on the first day of the Executive’s employment with the Company, which is anticipated to be April 1, 2024 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 12th, 2024 • Black Diamond Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (“Agreement”) is made between Black Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), and Melanie Morrison (the “Executive”) and is effective as of May 23, 2023 (the “Effective Date”). This Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the offer letter between the Executive and the Company dated August 31, 2022 (the “Prior Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • January 5th, 2024 • Prime Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”) is made between Prime Medicine, Inc., a Delaware corporation (the “Company”), and Allan Reine (the “Executive”) and is effective as of January 17th, 2024 (the “Effective Date”).
Employment AgreementEmployment Agreement • November 14th, 2023 • Absci Corp • Services-commercial physical & biological research • Washington
This Employment Agreement (“Agreement”) is made between Absci Corporation, a Delaware corporation (the “Company”), and Zachariah Jonasson (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 9th, 2023 • Black Diamond Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made between Black Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), and Elizabeth L. Montgomery (the “Executive”) and is effective as of February 22, 2022 (the “Effective Date”). This Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the offer letter between the Executive and the Company dated October 22, 2021 (the “Prior Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 9th, 2023 • Black Diamond Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made between Black Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), and Fang Z. Ni, Pharm.D. (the “Executive”) and is effective as of August 3, 2020 (the “Effective Date”). Except with respect to the Equity Documents (as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the offer letter between the Executive and the Company dated July 15, 2020 (the “Prior Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 9th, 2023 • Cullinan Oncology, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made between Cullinan Management, Inc., a Delaware corporation (the “Company”), and Jeff Trigilio (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Equity Documents (as defined below) and subject to Section 10 below, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated August 25, 2020 (the “Prior Agreement”), and (ii) any offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • October 13th, 2022 • Prime Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”) is made between Prime Medicine, Inc., a Delaware corporation (the “Company”), and [__________] (the “Executive”) and is effective as of [______] (the “Effective Date”).
AMENDED & RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • September 23rd, 2022 • Prime Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (this “Agreement”) is made between Prime Medicine, Inc., a Delaware corporation (the “Company”), and Carman Alenson (the “Executive”) to amend and restate that certain employment agreement between the Company and the Executive dated as of April 25, 2022 (the “2022 Prior Agreement”). This Agreement amends and restates the 2022 Prior Agreement and is effective upon the execution of the parties (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment agreement between the Executive and the Company executed June 7, 2021 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • September 23rd, 2022 • Prime Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (this “Agreement”) is made between Prime Medicine, Inc., a Delaware corporation (the “Company”), and Meredith Goldwasser, ScD (the “Executive”) to amend and restate that certain employment agreement between the Company and the Executive dated as of April 15, 2022 (the “2022 Prior Agreement”). This Agreement amends and restates the 2022 Prior Agreement and is effective upon the execution of the parties (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment agreement between the Executive and the Company executed September 6, 2020 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
AMENDED & RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • September 23rd, 2022 • Prime Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (this “Agreement”) is made between Prime Medicine, Inc., a Delaware corporation (the “Company”), and Jeremy Duffield, M.D., Ph.D. (the “Executive”) to amend and restate that certain employment agreement between the Company and the Executive dated as of April 15, 2022 (the “2022 Prior Agreement”). This Agreement amends and restates the 2022 Prior Agreement and is effective upon the execution of the parties (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment agreement between the Executive and the Company executed December 8, 2020 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
AMENDED & RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • September 23rd, 2022 • Prime Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (this “Agreement”) is made between Prime Medicine, Inc., a Delaware corporation (the “Company”), and Ann Lee, PhD (the “Executive”) to amend and restate that certain employment agreement between the Company and the Executive dated as of April 15, 2022 (the “2022 Prior Agreement”). This Agreement amends and restates the 2022 Prior Agreement and is effective upon the execution of the parties (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment agreement between the Executive and the Company dated as of September 21, 2021 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
AMENDED & RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • September 23rd, 2022 • Prime Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (this “Agreement”) is made between Prime Medicine, Inc., a Delaware corporation (the “Company”), and Keith M. Gottesdiener, M.D. (the “Executive”) to amend and restate that certain employment agreement between the Company and the Executive dated as of April 7, 2022 (the “2022 Prior Agreement”). This Agreement amends and restates the 2022 Prior Agreement and is effective upon the execution of the parties (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment agreement between the Executive and the Company dated as of June 24, 2020 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
AMENDED & RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 5th, 2022 • Prime Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (this “Agreement”) is made between Prime Medicine, Inc., a Delaware corporation (the “Company”), and Ann Lee, PhD (the “Executive”) to amend and restate that certain employment agreement between the Company and the Executive dated as of April 15, 2022 (the “2022 Prior Agreement”). This Agreement amends and restates the 2022 Prior Agreement and is effective upon the execution of the parties (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment agreement between the Executive and the Company dated as of September 21, 2021 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
AMENDED & RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 5th, 2022 • Prime Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (this “Agreement”) is made between Prime Medicine, Inc., a Delaware corporation (the “Company”), and Jeremy Duffield, M.D., Ph.D. (the “Executive”) to amend and restate that certain employment agreement between the Company and the Executive dated as of April 15, 2022 (the “2022 Prior Agreement”). This Agreement amends and restates the 2022 Prior Agreement and is effective upon the execution of the parties (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment agreement between the Executive and the Company executed December 8, 2020 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • May 6th, 2022 • Prime Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”) is made between Prime Medicine, Inc., a Delaware corporation (the “Company”), and Ann Lee, PhD (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment agreement between the Executive and the Company dated as of September 21, 2021 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • May 6th, 2022 • Prime Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”) is made between Prime Medicine, Inc., a Delaware corporation (the “Company”), and Meredith Goldwasser, ScD (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment agreement between the Executive and the Company executed September 6, 2020 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • May 6th, 2022 • Prime Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”) is made between Prime Medicine, Inc., a Delaware corporation (the “Company”), and Keith M. Gottesdiener, M.D. (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment agreement between the Executive and the Company dated as of June 24, 2020 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • May 6th, 2022 • Prime Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”) is made between Prime Medicine, Inc., a Delaware corporation (the “Company”), and Carman Alenson (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment agreement between the Executive and the Company executed June 7, 2021 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • May 6th, 2022 • Prime Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”) is made between Prime Medicine, Inc., a Delaware corporation (the “Company”), and Jeremy Duffield, M.D., Ph.D. (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment agreement between the Executive and the Company executed December 8, 2020 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • March 30th, 2022 • Centessa Pharmaceuticals PLC • Pharmaceutical preparations • Massachusetts
This Employment Agreement (this “Agreement”) is made by and between Centessa Pharmaceuticals, Inc. (the “U.S. Subsidiary”), a wholly owned subsidiary of Centessa Pharmaceuticals plc (“Parent”, with Parent, the U.S. Subsidiary and their respective subsidiaries and other affiliates referred to herein as the “Company”) and Saurabh Saha (the “Executive”) and is effective as of March 30, 2022 (the “Effective Date”). This Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment offer letter between the Executive and the Company dated as of November 19, 2020, revised on December 2, 2020 (the “Prior Agreement”) and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • March 30th, 2022 • Centessa Pharmaceuticals PLC • Pharmaceutical preparations • Delaware
This Employment Agreement (this “Agreement”) is made by and between Centessa Pharmaceuticals, Inc. (the “U.S. Subsidiaries”), a wholly owned subsidiary of Centessa Pharmaceuticals plc (“Parent”, with Parent, the US Subsidiary and their respective subsidiaries and other affiliates referred to herein as the “Company”) and Gregory M. Weinhoff (the “Executive”) and is effective as of March 30, 2022 (the “Effective Date”). This Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment offer letter between the Executive and the Company dated as of February 27, 2021 (the “Prior Agreement”) and (ii) any other offer letter, employment agreement or severance agreement.
